Chao Ni

Dr. Chao Ni


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
CNChao Ni
Chao Ni
LYLiu Yang
Liu Yang
QXQiuran Xu
Qiuran Xu
HYHongjun Yuan
Hongjun Yuan
WWWei Wang
Wei Wang
KYKun Yu
Kun Yu
Studies have indicated the significance of tumor associated macrophages (TAMs) in breast cancer; however, inconsistent results still exist. We retrospectively reviewed the macrophage distribution in 1579 breast cancer specimens with anti-CD68 or anti-CD163 immunohistochemical staining, and further analyzed the overall survival data. Furthermore, we performed a retrospective study and systematic review of the published studies on CD68- and CD163-positive macrophages in non-metastatic breast cancer. 13 studies with 5116 patients were included in this meta-analysis. Our own data revealed a high density of both CD68- and CD163-positive TAMs that was significantly related to lymph node metastasis (CD68, P = 0.003; CD163, P < 0.001); high Ki67 (CD68, P = 0.026; CD163, P < 0.001), poor histological grade (CD68, P < 0.001; CD163, P < 0.001) and hormonal receptor negativity (CD68, P < 0.001; CD163, P < 0.001); only CD163-positive TAMs were associated with poor overall survival (P = 0.003). Nonetheless, the meta-analysis only found that CD68- and CD163-positive TAMs were associated with high Ki67 [CD68, Relative risk (RR): 1.18, 95% confidence interval (CI): 1.09-1.28; CD163, RR: 1.75, 95% CI: 1.39-2.20], advanced histological grade (CD68, RR: 1.72, 95% CI: 1.46-2.03; CD163, RR: 1.99, 95% CI: 1.35-2.94) and low hormonal receptor levels (CD68, RR: 0.75, 95% CI: 0.69-0.82; CD163, RR: 0.82, 95% CI: 0.74-0.90), but not lymph node metastasis and HER2 expression. This meta-analysis further supports the clinical significance of TAMs in breast cancer, and both CD68- and CD163-positive TAMs could be prognostic markers in non-metastatic breast cancer.

1 September 2019 in Peptides
Verified
Journal Article
Closed access
XYXiao Ye
Xiao Ye
YSYiMin Shen
YiMin Shen
CNChao Ni
Chao Ni
JYJun Ye
Jun Ye
YXYubo Xin
Yubo Xin
YRYuezhong Ren
Yuezhong Ren

1 December 2013 in Protein Expression and Purification
Verified
Journal Article
Closed access
DBDawei Bu
Dawei Bu
YZYuwei Zhou
Yuwei Zhou
JTJian Tang
Jian Tang
FJFang Jing
Fang Jing
CNChao Ni
Chao Ni

8 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
SFShan Fang
Shan Fang
JZJun Zhang
Jun Zhang
CHChengyan Han
Chengyan Han
MKMingxiang Kong
Mingxiang Kong
HZHaibo Zhang
Haibo Zhang
CNChao Ni
Chao Ni
Background: The pathological response to neoadjuvant chemotherapy (NAC) has become a vital prognostic indicator for patients with breast cancer (BC). The newly generated models depended on rather basic imaging and pathology characteristics and did not sufficiently elucidate the importance of the incorporated data. The purpose of this study is to establish and authenticate a machine learning model for predicting the pathological complete response to NAC using baseline clinical and pathological features in BC patients. Methods: Data were collected from hospitalized BC patients treated with NAC at Zhejiang Provincial People's Hospital between January 2014 and August 2023. The dataset was randomly split, with 70% allocated for model training and 30% for validation. LASSO regression was used to select predictive features. Six ML models—XGBoost, LightGBM, CatBoost, logistic regression, random forest (RF), and support vector machine (SVM)—were developed, with performance assessed using the area under the curve (AUC) and accuracy, precision, recall, F1 score, and Brier score. Clinical benefits were evaluated using decision curve analysis (DCA), and SHapley Additive exPlanation (SHAP) was applied to interpret the features of the optimal ML model. Results: A total of 303 bc patients treated with NAC were included, with a pCR rate of 29.37% (89/303). Twelve features, such as age, menopausal status, PR, HER2 status, Ki‐67 expression, stromal tumor‐infiltrating lymphocytes (sTILs) et al., were selected for model construction. Among the six models, the CatBoost model demonstrated the best predictive performance, achieving an AUC of 0.853 after Bayesian hyperparameter tuning. SHAP analysis ranked sTILs as the most critical predictive feature. In fivefold cross‐validation, the CatBoost model incorporating sTILs achieved an average AUC of 0.83. Conclusions: The ML ‐based pCR prediction model enables more accurate pCR prediction for BC patients at baseline, aiding in optimizing treatment strategies. Additionally, the interpretable SHAP framework enhances model transparency, fostering clinical trust, and understanding among doctors.

21 October 2015 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
QYQin Yang
Qin Yang
YZYong Zhou
Yong Zhou
FLFu-Yu Li
Fu-Yu Li
HMHui Mao
Hui Mao
ASAnuj Shrestha
Anuj Shrestha
CNChao Ni
Chao Ni

17 June 2026 in Molecular Cancer
Verified
Journal Article
Open access
CNChao Ni
Chao Ni
YYYao Yao
Yao Yao
YWYimeng Wang
Yimeng Wang
LSLesang Shen
Lesang Shen
JDJinghua Ding
Jinghua Ding
CNChao Ni
Chao Ni
Despite widespread use of ultrasound and mammography, the accuracy of early breast cancer detection remains suboptimal, particularly in Asian women with dense breast tissue, underscoring the unmet need for biologically informed, non-invasive diagnostic approaches. Notably, systematic characterization of circulating proteomic and metabolomic alterations in early-stage breast cancer remains limited, especially in large, well-validated cohorts. Here, leveraging a registered multicenter prospective study (NCT06016790) together with an independent external validation cohort, we enrolled 662 participants across nine healthcare institutions to evaluate a plasma-based multi-omics liquid-biopsy framework for non-invasive detection. Data-independent acquisition proteomics and untargeted metabolomics profiled 5,549 proteins and 630 metabolites, with targeted validation performed in independent cohorts. Integrated analyses revealed coordinated molecular remodeling characterized by enrichment of cytoskeleton- and adhesion-associated proteins (for example ACTN1, VCL, ITGA2B and MYH9) together with rewiring of lipid-metabolic pathways. Network and trajectory modeling further identified 13 malignancy-associated protein modules and two progression-linked metabolic trajectories. Based on these features, we developed ProMeta-BC, a combined plasma proteome-metabolome model incorporating 15 proteins and 5 metabolites, which achieved robust discrimination between benign and malignant lesions (AUC 0.973 and 0.951 in training and validation cohorts, respectively), and ProMeta-BC-LN for prediction of axillary lymph-node metastasis (AUC 0.841 and 0.753). Notably, in cases with discordant radiological and pathological findings, the model detected 8 of 9 imaging-negative cancers and correctly reclassified 38 of 56 patients with inconsistent lymph-node calls, indicating complementary clinical utility. Together, these findings show that coordinated molecular signatures encoded in the circulating proteome-metabolome capture disease-relevant biology and provide a scalable, interpretable framework for non-invasive detection and stratification in breast cancer.